Uncategorized BlossomHill Therapeutics Closes $100 Million Series B Financing SAN DIEGO, Calif. – February 29, 2024 –BlossomHill Therapeutics, Inc., a biotechnology company focused on…Cassandra BurnsFebruary 29, 2024
Uncategorized BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering SAN DIEGO, Calif. – February 14, 2024 – BlossomHill Therapeutics, a biotechnology company focused on…Cassandra BurnsFebruary 14, 2024
Uncategorized BlossomHill Therapeutics Closes $71M Series A Financing BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced today that…bhtheraMarch 3, 2021
Recent Comments